Palisade Bio (PALI) Expected to Announce Earnings on Monday

Palisade Bio (NASDAQ:PALI) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($2.39) by $1.70. On average, analysts expect Palisade Bio to post $-12 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Palisade Bio Trading Down 5.2 %

Shares of NASDAQ PALI opened at $0.73 on Friday. The firm has a market cap of $3.19 million, a price-to-earnings ratio of -0.05 and a beta of 1.46. Palisade Bio has a 1-year low of $0.60 and a 1-year high of $6.90. The stock has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $1.49.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.